Biofrontera Receives FDA Approval for Ameluz Expansion
Recently, Biofrontera Inc. announced significant news regarding its flagship product, Ameluz (aminolevulinic acid HCl) topical gel. The U.S. Food and Drug Administration (FDA) has officially approved a supplemental New Drug Application (sNDA) allowing the use of up to three tubes of Ameluz in a single photodynamic therapy (PDT) treatment for actinic keratosis (AK) on the face and scalp. This momentous approval is expected to enhance the standard of care for patients dealing with this common skin condition.
Wider Treatment Options for Actinic Keratosis
With this new approval, healthcare professionals now have the flexibility to treat larger fields effectively. The use of three tubes of Ameluz per session ensures that dermatologists can address greater or multiple treatment areas at once. This change not only benefits patients but also makes procedures more convenient for healthcare practitioners who perform PDT.
Implications of the Approval
Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc., expressed his enthusiasm about the FDA's decision. He stated, “We are thrilled with the FDA's decision to approve the use of up to three tubes of Ameluz per treatment. Our next steps involve working with Medicare and private payers to secure reimbursement for this expanded usage.”
Clinical Studies Supporting the Approval
The sNDA submitted by Biofrontera was supported by two pivotal Phase I safety studies, involving 116 participants in total. These studies demonstrated that the blood concentrations of the active component and its metabolite remained significantly below levels associated with side effects. The adverse events observed were comparable to those when only one tube of Ameluz was administered, establishing the treatment’s safety and efficacy.
Understanding Actinic Keratosis
Actinic keratosis represents the most prevalent pre-cancerous skin lesion resulting from long-term sun exposure. If neglected, these lesions can progress into the more serious squamous cell carcinoma. Regions most affected typically include sun-exposed skin areas such as the face, bald scalp, arms, and the backs of hands. A staggering estimate reveals that around 58 million Americans were afflicted by AK in recent years, with 13 million treatments performed annually.
The Role of Ameluz in Treatment
Ameluz is recognized as the sole PDT photosensitizer approved by the FDA that can be utilized for both lesion-directed and field-directed treatments of AK. Dr. Jonathan Weiss, an investigator and a co-managing partner at Georgia Dermatology Partners, has relied on Ameluz for over seven years for AK management due to its proven efficacy and safety. He remarked, “With the newer approval, I am eager to utilize up to three tubes for patients who require this level of treatment.”
About Biofrontera Inc.
Biofrontera Inc. is dedicated to advancing dermatological care. This U.S.-based biopharmaceutical company is focused on the development and commercialization of innovative therapies, particularly aimed at treating skin conditions through PDT. The company’s flagship product, Ameluz, is administered alongside the RhodoLED lamp series, specifically designed for effective PDT of AK and related skin disorders. They are also actively conducting clinical trials to explore broader applications, including treatment for non-melanoma skin cancers and severe acne.
Frequently Asked Questions
What is Ameluz approved for?
Ameluz is FDA-approved for the treatment of actinic keratosis (AK) using photodynamic therapy (PDT).
How many tubes of Ameluz can be used now?
With the latest FDA approval, healthcare providers can now use up to three tubes of Ameluz in a single treatment.
What does this approval mean for patients?
This approval enables doctors to treat larger areas affected by AK, thus providing more comprehensive care options for patients.
Has Ameluz been tested for safety?
Yes, the sNDA was supported by Phase I safety studies that demonstrated the treatment's safety and showed minimal side effects.
What is the significance of treating AK?
Treating AK is crucial because untreated lesions can lead to squamous cell carcinoma, making effective management vital.
